CU20200039A7 - Mitoflavoscinas: la fijación como objetivo de enzimas que contienen flavina elimina células madre cancerosas (cscs) al inhibir la respiración mitocrondrial - Google Patents

Mitoflavoscinas: la fijación como objetivo de enzimas que contienen flavina elimina células madre cancerosas (cscs) al inhibir la respiración mitocrondrial

Info

Publication number
CU20200039A7
CU20200039A7 CU2020000039A CU20200039A CU20200039A7 CU 20200039 A7 CU20200039 A7 CU 20200039A7 CU 2020000039 A CU2020000039 A CU 2020000039A CU 20200039 A CU20200039 A CU 20200039A CU 20200039 A7 CU20200039 A7 CU 20200039A7
Authority
CU
Cuba
Prior art keywords
mitoflavoscins
cscs
inhibiting
stem cells
cancer stem
Prior art date
Application number
CU2020000039A
Other languages
English (en)
Inventor
Michael P Lisanti
Federica Sotgia
Original Assignee
Lunella Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lunella Biotech Inc filed Critical Lunella Biotech Inc
Publication of CU20200039A7 publication Critical patent/CU20200039A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C25/00—Compounds containing at least one halogen atom bound to a six-membered aromatic ring
    • C07C25/18—Polycyclic aromatic halogenated hydrocarbons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D347/00—Heterocyclic compounds containing rings having halogen atoms as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/12—Heterocyclic compounds containing pteridine ring systems containing pteridine ring systems condensed with carbocyclic rings or ring systems
    • C07D475/14—Benz [g] pteridines, e.g. riboflavin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G01N33/5079—Mitochondria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>La presente descripción se refiere a compuestos que se enlazan a enzimas que contienen flavina e inhiben la función mitocondrial, referidos en este documento como mitoflavoscinas. Se describen métodos para examinar compuestos por la inhibición mitocondrial y propiedades anticancerosas. También se describen métodos para usar mitoflavoscinas para prevenir o tratar el cáncer, infecciones bacterianas y levadura patógena, así como también métodos para usar mitoflavoscinas para proporcionar beneficios anti-envejecimiento. También se dan a conocer compuestos específicos de mitoflavoscinas.</p>
CU2020000039A 2017-10-24 2018-10-23 Mitoflavoscinas: la fijación como objetivo de enzimas que contienen flavina elimina células madre cancerosas (cscs) al inhibir la respiración mitocrondrial CU20200039A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762576287P 2017-10-24 2017-10-24
PCT/US2018/057093 WO2019083997A1 (en) 2017-10-24 2018-10-23 MITOFLAVOSCINS: TARGETING FLAVIN-CONTAINING ENZYMES THAT REMOVE CANCER STEM CELLS (CSC) BY INHIBITING MITOCHONDRIAL BREATHING

Publications (1)

Publication Number Publication Date
CU20200039A7 true CU20200039A7 (es) 2021-03-11

Family

ID=66247987

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000039A CU20200039A7 (es) 2017-10-24 2018-10-23 Mitoflavoscinas: la fijación como objetivo de enzimas que contienen flavina elimina células madre cancerosas (cscs) al inhibir la respiración mitocrondrial

Country Status (20)

Country Link
US (1) US11497749B2 (es)
EP (1) EP3700512A4 (es)
JP (1) JP2021500374A (es)
KR (1) KR20200069365A (es)
CN (1) CN111565715A (es)
AU (1) AU2018354143A1 (es)
BR (1) BR112020008022A2 (es)
CA (1) CA3079952A1 (es)
CL (1) CL2020001108A1 (es)
CR (1) CR20200218A (es)
CU (1) CU20200039A7 (es)
EC (1) ECSP20027220A (es)
IL (1) IL274116A (es)
MX (1) MX2020004211A (es)
PE (1) PE20210166A1 (es)
PH (1) PH12020550476A1 (es)
RU (1) RU2020116649A (es)
SG (1) SG11202003675PA (es)
WO (1) WO2019083997A1 (es)
ZA (1) ZA202002663B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102017220539A1 (de) 2017-11-17 2019-05-23 Zf Friedrichshafen Ag Verfahren zum Betreiben eines Systems aus einem landwirtschaftlichen Arbeitsfahrzeug und zumindest einem an diesem angeordneten Arbeitsgerät
EP3717015A4 (en) * 2017-12-01 2021-07-28 Lunella Biotech, Inc. REPURPOSCINS: TARGET MITOCHONDRIAL BIOGENESIS INHIBITORS TO ERADICATE CARCINOUS STEM CELLS
WO2019232161A1 (en) 2018-06-01 2019-12-05 Lunella Biotech, Inc. Biomarkers and therapeutics for endocrine therapy resistance
PE20211006A1 (es) 2018-10-02 2021-06-01 Lunella Biotech Inc Derivados de azitromicina y roxitromicina como farmacos senoliticos
EP3976197B1 (en) 2019-05-24 2025-07-16 Lunella Biotech, Inc. Therapeutics and methods for predicting and overcoming endocrine resistance in breast cancer
CN116159135B (zh) * 2021-11-25 2026-02-17 深圳先进技术研究院 细胞穿透的核黄素复合物及其在制备光动力治疗药物中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9321558D0 (en) * 1993-10-19 1993-12-08 Radopath Ltd Anti-viral agents
JPH09309874A (ja) * 1996-05-21 1997-12-02 Fuji Photo Film Co Ltd ポジ型感光性組成物
US6498181B1 (en) * 1999-01-06 2002-12-24 Maxim Pharmaceuticals Synergistic tumorcidal response induced by histamine
AU779215B2 (en) * 1999-07-16 2005-01-13 Maxim Pharmaceuticals, Inc. Activation and protection of cytotoxic lymphocytes using a reactive oxygen metabolite inhibitor
JP2002221787A (ja) * 2001-01-25 2002-08-09 Fuji Photo Film Co Ltd ポジ型感放射線性組成物
JP4098483B2 (ja) 2001-03-12 2008-06-11 富士フイルム株式会社 平版印刷版原版
JP2003207898A (ja) * 2001-11-08 2003-07-25 Fuji Photo Film Co Ltd ポジ型レジスト組成物
CN1839142B (zh) * 2003-08-22 2010-06-16 澳新制药公司 用作靶向线粒体的抗氧化剂的线粒体醌衍生物
JP2005091713A (ja) * 2003-09-17 2005-04-07 Fuji Photo Film Co Ltd ポジ型レジスト組成物及びそれを用いたパターン形成方法。
GB0329716D0 (en) * 2003-12-23 2004-01-28 Amersham Plc Radical trap
WO2005099721A2 (en) * 2004-04-15 2005-10-27 The Regents Of The University Of California Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof
DE102007025423A1 (de) 2007-05-30 2008-12-04 Friedrich-Schiller-Universität Jena Triphenylphosphonium-Derivate zum gezielten Transport und Freisetzen von Substanzen in Mitochondrien sowie Verfahren zu deren Verwendung
JP2009057330A (ja) * 2007-08-31 2009-03-19 Aspion Kk ジフェニレンヨードニウム化合物
WO2009038656A1 (en) 2007-09-17 2009-03-26 Kosta Steliou Mitochondria-targeting antioxidant therapeutics
CN102439453A (zh) * 2009-05-20 2012-05-02 日内瓦大学 癌症起始细胞的线粒体活性抑制剂及其用途
JP5927518B2 (ja) * 2011-08-08 2016-06-01 イムノメット セラピューティクス インク Ｎ１−環状アミン−ｎ５−置換フェニルビグアニド誘導体、それの調製方法及びそれを含む医薬組成物
RU2522557C1 (ru) * 2013-04-09 2014-07-20 государственное бюджетное образовательное учреждение высшего профессионального образования "Сибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СибГМУ Минздрава России) СПОСОБ ПОЛУЧЕНИЯ п-ИОДФЕНИЛЖИРНЫХ КИСЛОТ
MD4626C1 (ro) 2013-04-24 2019-11-30 Smart Brain Sro Derivaţi de tamoxifen pentru tratamentul afecţiunilor neoplazice, în special cu nivel înalt de proteină HER2
WO2015002996A1 (en) 2013-07-01 2015-01-08 University Of Georgia Research Foundation, Inc. Precise delivery of therapeutic agents to cell mitochondria for anti-cancer therapy
AU2015244356A1 (en) * 2014-03-10 2016-10-27 Aravind Musuluri Augmenting search results
CN107137390A (zh) * 2017-06-09 2017-09-08 中国人民解放军第三军医大学第附属医院 氯化二亚苯基碘鎓在制备治疗细菌感染药物中的用途

Also Published As

Publication number Publication date
ZA202002663B (en) 2022-06-29
PE20210166A1 (es) 2021-01-28
CL2020001108A1 (es) 2020-10-23
PH12020550476A1 (en) 2021-03-15
US11497749B2 (en) 2022-11-15
RU2020116649A (ru) 2021-11-30
WO2019083997A1 (en) 2019-05-02
US20200246344A1 (en) 2020-08-06
JP2021500374A (ja) 2021-01-07
ECSP20027220A (es) 2020-06-30
MX2020004211A (es) 2020-08-13
CR20200218A (es) 2020-12-23
AU2018354143A1 (en) 2020-05-14
EP3700512A4 (en) 2021-08-11
EP3700512A1 (en) 2020-09-02
IL274116A (en) 2020-06-30
CA3079952A1 (en) 2019-05-02
SG11202003675PA (en) 2020-05-28
BR112020008022A2 (pt) 2020-10-27
CN111565715A (zh) 2020-08-21
KR20200069365A (ko) 2020-06-16

Similar Documents

Publication Publication Date Title
CU20200039A7 (es) Mitoflavoscinas: la fijación como objetivo de enzimas que contienen flavina elimina células madre cancerosas (cscs) al inhibir la respiración mitocrondrial
DOP2022000165A (es) MITORRIBOSCINAS: COMPUESTOS TERAPÉUTICOS BASADOS EN MITOCONDRIAS QUE FIJAN COMO OBJETIVO CÉLULAS CANCEROSAS, BACTERIAS y LEVADURAS PATÓGENAS
EP4219718A3 (en) Compositions and methods for modulating complement factor b expression
CU20170116A7 (es) Compuestos cíclicos terapéuticos como inmunomoduladores
UY37145A (es) Ligandos de direccionamiento
BR112015032921A8 (pt) compostos de benzofuranila e benzoxazolila substituídos e utilizações dos mesmos
MX2018002889A (es) Compuesto de pirimidina fusionada o sal del mismo.
BR112013002012A2 (pt) métodos e composições para terapia de câncer de fígado
CR20170014A (es) Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer
BR112014026058A2 (pt) composições para tratamento tópico de infecções microbianas
CR20120528A (es) Métodos para tratar el cáncer
MX2017007829A (es) Composicion antimicrobiana.
DOP2022000142A (es) Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosas
BR112012023836A2 (pt) composto tricíclicos e inibidores de pbk contendo os mesmos
BR112021025491A2 (pt) Métodos para uso de inibidores de rad51 para tratamento de câncer pancreático
CO2022000481A2 (es) Inhibidores de enzimas
WO2013112651A3 (en) Proteasome activity modulating compounds
DOP2013000051A (es) Compuestos heterociclico y sus usos
WO2020160453A8 (en) Modulators of yap1 expression
UY36213A (es) “aumento de la cosecha (rendimiento) de plantas de cultivo utilizando leyes termodinámicas en plantas completas para detectar períodos óptimos para necesidades de energía exotérmica en comparación con energía endotérmica”.
UY38024A (es) Compuestos de fluoralquenilo, proceso de preparación y uso de los mismos
BR112015025968A2 (pt) poliplexos
WO2018231034A3 (ko) 암의 예방 또는 치료용 약학적 조성물
BR102012013982A2 (pt) 5-fluorocitosina como um tratamento de semente
AR093094A1 (es) El uso de biocidas oxidantes y no oxidantes para el control de bacterias tolerantes al tratamiento de oxidante estabilizado